1
Home
Companies

Altamira Therapeutics

#10687

Rank

$1.13M

Marketcap

BM Bermuda

Country

Altamira Therapeutics
Leadership team

Dr. Thomas Meyer Ph.D. (Founder, Chairman, CEO & MD)

Mr. Marcel Gremaud CPA (Chief Financial Officer)

Dr. Samuel A. Wickline M.D. (Chief Scientific Officer)

Products/ Services
Analytics, Software, Software Engineering
Headquarters
Mclean, Virginia, United States
Established
1999
Company Registration
SEC CIK number: 0001601936
Traded as
CYTO
Social Media
URL
https://altamiratherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
History

Altamira Therapeutics was founded in 2017 by a team of leading scientists and healthcare entrepreneurs. The team had a shared vision to make a difference in patients’ lives by making novel therapies based on cell surface receptors. In 2018, the company formed strategic partnerships with leading academic institutions and granted exclusive licenses to its technology platform. The same year, the company closed its Series A financing round with leading venture capital investors in the biotechnology sector. In 2019, Altamira advanced its innovative programs and is developing its lead drug candidates in oncology and regenerative medicine datasets.

Mission
Our mission is to discover, develop, and commercialize transformative treatments based on modern diseases, enabling patients to dramatically change the course of their lives.
Vision
We aspire to be recognized by our peers and partners for our deep expertise in developing cell surface receptor-based therapies.
Key Team

Dr. Covadonga Paneda (Chief Devel. Officer)

Mr. Jean Lechance (Unit Head of OTC Consumer Health Bus.)

Recognition and Awards
Altamira Therapeutics has been recognized by numerous awards, including the 2017 Wall Street Badge for the Best Biotechnology Company, the 2018 San Diego Business Journal Fast 50 Award for Fastest Growing Company, and the 2019 Global Innovation Award for Start-Up of the Year.
References

https://in.investing.com/equities/auris-mdl-h

https://finance.yahoo.com/quote/CYTO/profile?p=CYTO

https://www.crunchbase.com/organization/altamira-aa96

https://companiesmarketcap.com/

https://altamiratherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Altamira Therapeutics
Leadership team

Dr. Thomas Meyer Ph.D. (Founder, Chairman, CEO & MD)

Mr. Marcel Gremaud CPA (Chief Financial Officer)

Dr. Samuel A. Wickline M.D. (Chief Scientific Officer)

Products/ Services
Analytics, Software, Software Engineering
Headquarters
Mclean, Virginia, United States
Established
1999
Company Registration
SEC CIK number: 0001601936
Traded as
CYTO
Social Media
URL
https://altamiratherapeutics.com